INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES

这是一项在胰岛素中摄入干扰素-α（IFN-α）的I期试验 依赖性糖尿病（IDDM），一种自身免疫性疾病。 它将研究 IFN-α对免疫功能和β细胞功能的影响， 在IDDM中销毁。 将入组新诊断的IDDM受试者 长达12个月的治疗期。 建立临床 通过摄入IFN-α改善或抑制免疫可能导致 安慰剂对照II-III期试验，持续改善 临床疾病作为主要结局。 8名患者入组，2名患者因非医学原因退出。 4名患者接受研究药物治疗12个月，2名患者已达到 六个月 这六个国家中有四个仍处于蜜月期。

This is a phase I trial of ingested interferon-alpha (IFN-a) in insulin dependent diabetes mellitus (IDDM), an autoimmune disease. It will study the effect of IFN-a on immune function and Beta cell function and destruction in IDDM. Subjects with newly diagnosed IDDM will be enrolled for a treatment period of up to 12 months. Establishment of clinical improvement or immunosuppression with ingested IFN-a may lead to a placebo-controlled phase II-III trial with persistent improvement in clinical disease as a primary outcome. Eight patients were enrolled, and two withdrew for non-medical reasons. Four patients were on study medication for 12 months, and two have reached six months. Four of the six are still in the honeymoon period.